Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Speculating in Takeover Targets -- Ignore unavailable to you. Want to Upgrade?

To: richardred who wrote (357)	1/2/2004 2:04:29 PM
From: Jack Hartmann	Respond to of 7256

Good Focus. I see Merck having to pick some biotechs to boost their pipeline.

To: richardred who wrote (357)	2/16/2004 1:33:16 PM
From: richardred	Read Replies (2) \| Respond to of 7256

German Mercks focus -Generics they will have cash over a billion from the sale of VWR. "We can afford a lot as per our present balance sheet," he said when asked about the size of Merck's acquisition war chest. "It's a question of what we want. In generics, we will certainly look around."

To: richardred who wrote (357)	4/7/2004 1:03:22 PM
From: richardred	Respond to of 7256

DJ Bentley Pharma Gets OK To Mkt Generic Mirtazapine Anti Depressant In Spain>BNT Dow Jones News Service ~ April 7, 2004 ~ 7:02 am EST

To: richardred who wrote (357)	12/1/2004 9:49:53 AM
From: richardred	Respond to of 7256

RE:post 357-After a Year,I still like the area. Teva Closes Acquisition of Pfizer's Italian Generic Pharmaceutical Operation - Dorom Wednesday December 1, 9:32 am ET JERUSALEM--(BUSINESS WIRE)--Dec. 1, 2004--Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA - News) announced today, further to its announcement dated August 17, 2004, that it has completed its cash acquisition, of Pfizer's Italian generic pharmaceutical marketing company, Dorom S.r.l., one of the largest suppliers of generic pharmaceuticals to the Italian retail market. Teva Italy will integrate Dorom's business into its own pharmaceutical activities and will actively promote the product lines of both companies. Subsequent to this acquisition, Teva, which is the largest generic company in Italy, will further strengthen its leading position in this important and growing market. The combined company, Teva Italy, will have a product portfolio of 77 generic products (in 150 presentations) available to the Italian market and 63 products in the pipeline (in 122 presentations) of pending generic product registrations. Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 25 pharmaceutical companies and among the largest generic pharmaceutical companies in the world. The company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients. Close to 90% of Teva's sales are in North America and Europe. Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on management's current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause Teva's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include Teva's ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competitive generic products, the impact of competition from brand-name companies that sell or license their own generic products (so called "authorized generics") or successfully extend the exclusivity period of their branded products, the effects of competition on Copaxone® sales, including potential competition from the expected launch of Tysabri®/Antegren®, Teva's ability to rapidly integrate the operations of acquired businesses, including its acquisition of Sicor Inc., regulatory changes that may prevent Teva from exploiting exclusivity periods, potential liability for sales of generic products prior to completion of appellate litigation, including that relating to Neurontin, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Association and other regulatory authority approvals, the regulatory environment and changes in the health policies and structure of various countries, Teva's ability to successfully identify, consummate and integrate acquisitions, exposure to product liability claims, dependence on patent and other protections for innovative products, significant operations outside the United States that may be adversely affected by terrorism or major hostilities, fluctuations in currency, exchange and interest rates, operating results and other factors that are discussed in Teva's Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise. -------------------------------------------------------------------------------- Contact: Teva Pharmaceutical Industries Ltd. Dan Suesskind, 011-972-2-589-2840 or Teva North America Bill Fletcher, 215-591-8800 or Investor Relations: Teva Pharmaceutical Industries Ltd. Dorit Meltzer, 011-972-3-926-7554 Web Site: www.tevapharm.com biz.yahoo.com